DOCSLIB.ORG

Procedure Description Charge Amount 0302000014 ROOM MED

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Charge Procedure Description Amount 0302000014 ROOM MED SURG MOSU 1,040.00 0302000015 ROOM MED SURG PEDS 3,500.00 0302000033 OUT PATIENT BED MOSU 0.00 0302000035 ROOM INTERMEDIATE MOSU 2,055.00 0302000043 ROOM HOSPICE MOSU 805.00 0302000045 ROOM MED SURG W TELE MOSU 1,530.00 0302000050 OBSERVATION INTERM PER HR MOSU 97.00 0302002283 FECAL MANAGEMENT SYSTEM 694.00 0302010232 CATH INDWELL BLADDER SIMPLE 185.00 0302010304 OBSERVATION MS PER HR MOSU 60.00 0302010305 OBSERVATION TELE PER HR MOSU 71.00 0302010556 NONBILLABLE OBSERVATION HR 0.00 0302010557 OBSERVATION DIRECT ADM MOSU 130.00 0302020287 SUPPLIES CHEST TUBE 228.00 0302050318 LUMBAR PUNCTURE DIAGNOSTIC 1,035.00 0302050451 IV INF THERAPEUTIC EA ADD HR 170.00 0302050453 IV INF THERAPEUTIC UP TO 1HR 635.00 0302050454 IRRIGATION BLADDER 780.00 0302050480 INSERT VENOUS CENTRAL LINE 1,315.00 0302050490 IV PUSH INITIAL DRUG 380.00 0302050534 I&D ABSCESS SIMPLE 675.00 0302050603 IV PUSH EA SEQUENTIAL DRUG 153.00 0302050648 HEMODIALYSIS SERVICE IP 1,455.00 0302050813 ARTHROCENTESIS MAJ JNT WO IMAG 630.00 0302050885 ADMIN IMMUNIZATION 145.00 0302050948 DIALYSIS INTRAPERITONEAL SERV 655.00 0302060002 INJECTION SUB-Q/IM 155.00 0302060008 CHEMO ADMIN IV INF EA ADD HR 410.00 0302060101 HEMODIALYSIS SERVICE OBS/OP 1,455.00 0302060269 US PV RESIDUAL URINE 240.00 0302060274 IV PUSH EA ADD DRUG 168.00 0302060275 IV INF CONCURRENT THERAPEUTIC 385.00 0302060276 IV INF SEQUENTIAL THER UP TO 1 191.00 0302060293 INSERT STRAIGHT CATH THERAPEUT 185.00 0302060372 CHEMO ADMIN IV INF SEQ 1 HR 525.00 0302060373 IV INF HYDRATION EA ADD HR 138.00 0302060374 IV INF HYDRATION UP TO 1HR 430.00 0302060696 BLOOD TRANSFUSION DAILY 1,250.00 0302061072 PLASMAPHERESIS SERVICE 2,965.00 0302061208 PORT FLUSH 190.00 0302090028 DEBRID OPEN WOUND <20SQCM 415.00 0302090112 DECLOG PERM CATH W THROMBO 760.00 0302090136 ADMIN INFLUENZA VACCINE 94.00 0302090137 ADMIN PNEUMOCOCCAL VACCINE 84.00 0303250810 PUNCTURE ASPIRATION 605.00 0302600006 ROOM INTERMEDIATE SURG 2,055.00 0302600015 ROOM MED SURG SURGICAL 1,040.00 0302600033 OUT PATIENT BED 0.00 0302600043 ROOM HOSPICE SURG 805.00 0302600045 ROOM MED SURG W TELE SURGICAL 1,530.00 0302602283 FECAL MANAGEMENT SYSTEM 694.00 0302610232 CATH INDWELL BLADDER SIMPLE 185.00 0302610304 OBSERVATION MS PER HR SURGICAL 60.00 0302610305 OBSERVATION W TELE PER HR SURG 71.00 0302610556 NONBILLABLE OBSERVATION HR 0.00 0302610557 OBSERVATION DIRECT ADM SURG 130.00 0302622411 PREVENA 125 THERAPY UNIT KIT 1,337.00 0302650260 REPAIR SMP SCLP/TRNK/E 2.6-7.5 310.00 0302650451 IV INF THERAPEUTIC EA ADD HR 170.00 0302650453 IV INF THERAPEUTIC UP TO 1HR 635.00 0302650454 IRRIGATION BLADDER 780.00 0302650484 INJECTION SUB-Q/IM 155.00 0302650490 IV PUSH INITIAL DRUG 380.00 0302650539 I&D ABSCESS COMPLICATED 1,155.00 0302650603 IV PUSH EA SEQUENTIAL DRUG 153.00 0302650648 HEMODIALYSIS SERVICE IP 1,455.00 0302650813 ARTHROCENT MAJOR JOINT/BURSA 630.00 0302650885 ADMIN IMMUNIZATION 145.00 0302650948 DIALYSIS INTRAPERITONEAL SERVI 655.00 0302660101 HEMODIALYSIS SERVICE OBS/OP 1,455.00 0302660269 US PV RESIDUAL URINE 240.00 0302660274 IV PUSH EA ADD DRUG 168.00 0302660275 IV INF CONCURRENT THERAPEUTIC 385.00 0302660276 IV INF SEQUENTIAL THER UP TO 1 191.00 0302660293 INSERT STRAIGHT CATH THERAPEUT 185.00 0302660373 IV INF HYDRATION EA ADD HR 138.00 0302660374 IV INF HYDRATION UP TO 1HR 430.00 0302660696 BLOOD TRANSFUSION DAILY 1,250.00 0302661072 PLASMAPHERESIS SERVICE 2,965.00 0302690136 ADMIN INFLUENZA VACCINE 94.00 0302690137 ADMIN PNEUMOCOCCAL VACCINE 84.00 0302900006 ROOM INTERMEDIATE PCU 2,055.00 0302900033 OUT PATIENT BED 0.00 0302900041 ROOM MED SURG PCU 1,040.00 0302900043 ROOM HOSPICE PCU 805.00 0302900049 ROOM MED SURG W TELE PCU 1,530.00 0302900050 OBSERVATION INTERM PER HR PCU 97.00 0302902283 FECAL MANAGEMENT SYSTEM 694.00 0302910232 INSERTION FOLEY CATHETER 185.00 0302910304 OBSERVATION MS PER HR PCU 60.00 0302910305 OBSERVATION TELE PER HOUR 71.00 0302910556 NONBILLABLE OBSERVATION HR 0.00 0302910557 OBSERVATION DIRECT ADM PCU 130.00 0302920287 CHEST TUBE INSERTION SUPPLIES 228.00 0302950262 REPAIR SMP SCLP/TRNK/EXT <2.5C 500.00 0302950318 LUMBAR PUNCTURE DIAGNOSTIC 1,035.00 0302950451 IV INF THERAPEUTIC EA ADD HR 170.00 0302950453 IV INF THERAPEUTIC UP TO 1HR 635.00 0302950454 IRRIGATION BLADDER 780.00 0302950484 INJECTION SUB-Q/IM 155.00 0302950490 IV PUSH INITIAL DRUG 380.00 0302950497 INJECTION PERIPHERAL NERVE BLO 1,085.00 0302950603 IV PUSH EA SEQUENTIAL DRUG 153.00 0302950648 HEMODIALYSIS SERVICE IP 1,455.00 0302950885 ADMININSTRATION IMMUNIZATION 145.00 0302950948 DIALYSIS INTRAPERITONEAL SERV 655.00 0302960101 HEMODIALYSIS SERVICE OBS/OP 1,455.00 0302960269 US PV RESIDUAL URINE 240.00 0302960274 IV PUSH EA ADD DRUG 168.00 0302960275 IV INF CONCURRENT THERAPEUTIC 385.00 0302960276 IV INF SEQUENTIAL THER UP TO 1 191.00 0302960293 INSERT STRAIGHT CATH THERAPEUT 185.00 0302960373 IV INF HYDRATION EA ADD HR 138.00 0302960374 IV INF HYDRATION UP TO 1HR 430.00 0302960680 NERVE BLK GREATER OCCIPITAL 900.00 0302960696 BLOOD TRANSFUSION DAILY 1,250.00 0302960777 NERVE BLOCK TRIGEMINAL 830.00 0302960801 CATH FOR URINE SPECIMEN 23.00 0302961072 PLASMAPHERESIS SERVICE 2,965.00 0302961208 PORT FLUSH 190.00 0302990112 DECLOG PERM CATH W THROMBO 760.00 0302990136 ADMIN INFLUENZA VACCINE 94.00 0302990137 ADMIN PNEUMOCOCCAL VACCINE 84.00 0323050996 PUNCTURESHUNT ASP OR INJ 900.00 0303560293 CATHERIZATION STRAIGHT 185.00 0303400015 ROOM MED SURG PEDS 3,500.00 0303400033 OUT PATIENT BED 0.00 0303400041 ROOM MED SURG 1,040.00 0303410085 CIRCUMCISION PROCEDURE PEDS 405.00 0303410232 INSERTION FOLEY CATHETER 185.00 0303410304 OBSERVATION MS PER HOUR PEDS 104.00 0303410556 NONBILLABLE OBSERVATION HR 0.00 0303410557 OBSERVATION DIRECT ADM PEDS 130.00 0303440608 RECOVERY PHASE II PER 30 MIN 280.00 0303450318 PUNCTURE SPINAL/LUMBAR 1,035.00 0303450451 IV INF THERAPEUTIC EA ADD HR 170.00 0303450453 IV INF THERAPEUTIC UP TO 1HR 635.00 0303450484 INJECTION SUB-Q/IM 155.00 0303450490 IV PUSH INITIAL DRUG 380.00 0303450603 IV PUSH EA SEQUENTIAL DRUG 153.00 0303450763 CHEMO IV PUSH INITIAL DRUG 860.00 0303450764 CHEMO ADMIN SUBQ/IM NON HORMON 410.00 0303450885 ADMININSTRATION IMMUNIZATION 145.00 0303450919 ADMIN IMMUNIZATION EA ADD VACC 60.00 0303460005 CHEMO ADMIN IV INFUSION 1 HR 945.00 0303460008 CHEMO ADMIN IV INF EA ADD HR 410.00 0303460101 HEMODIALYSIS SERVICE OBS/OP 1,455.00 0303460263 ADMIN TB SKIN TEST 84.00 0303460269 US PV RESIDUAL URINE 240.00 0303460274 IV PUSH EA ADD DRUG 168.00 0303460275 IV INF CONCURRENT THERAPEUTIC 385.00 0303460276 IV INF SEQUENTIAL THER UP TO 1 191.00 0303460293 INSERT STRAIGHT CATH THERAPEUT 185.00 0303460371 CHEMO IV PUSH EA ADD DRUG 605.00 0303460372 CHEMO ADMIN IV INF SEQ 1 HR 525.00 0303460373 IV INF HYDRATION EA ADD HR 138.00 0303460374 IV INF HYDRATION UP TO 1HR 430.00 0303460541 BLD DRAW W COMPLETLY IMPL VAD 230.00 0303460542 BLOOD DRAW FROM PERIPH VAD PIC 150.00 0303460696 BLOOD TRANSFUSION DAILY 1,250.00 0303460801 CATH FOR URINE SPECIMEN 21.00 0303460804 NURSING E/M ESTAB LVL 1 125.00 0303460805 NURSING E/M ESTAB LVL 2 200.00 0303460806 NURSING E/M ESTAB LVL 3 250.00 0303460807 NURSING E/M ESTAB LVL 4 350.00 0303460808 NURSING E/M ESTAB LVL 5 425.00 0303460809 NURSING E/M NEW LVL 1 175.00 0303460810 NURSING E/M NEW LVL 2 250.00 0303460811 NURSING E/M NEW LVL 3 325.00 0303460812 NURSING E/M NEW LVL 4 270.00 0303460813 NURSING E/M NEW LVL 5 525.00 0303460918 HEMODIALYSIS SERV NON ESRD OP 1,455.00 0303461072 PLASMAPHERESIS SERVICE 2,965.00 0303461162 CHEMICAL CAUTERY TISSUE 415.00 0303461208 PORT FLUSH 190.00 0303461270 CAR SEAT TEST 1 HOUR 150.00 0303461271 CAR SEAT TEST EA ADD 30 MIN 50.00 0303490112 DECLOG PERM CATH W THROMBO 760.00 0303490136 ADMIN INFLUENZA VACCINE 94.00 0303490137 ADMIN PNEUMOCOCCAL VACCINE 84.00 0303500014 ROOM MED SURG W TELE CVCU 1,530.00 0303500033 OUT PATIENT BED 0.00 0303500035 ROOM INTERMEDIATE CVCU 2,055.00 0303500036 ROOM CRITICAL CVCU 2,875.00 0303500041 ROOM MED SURG CVCU 1,040.00 0303500043 ROOM HOSPICE CVCU 805.00 0303500050 OBSERVATION INTERM PER HR CVCU 97.00 0303502283 FECAL MANAGEMENT SYSTEM 694.00 0303510232 INSERTION FOLEY CATHETER 185.00 0303510304 OBSERVATION MS PER HOUR CVCU 60.00 0303510305 OBSERVATION TELE PER HR CVCU 71.00 0303510556 NONBILLABLE OBSERVATION HR 0.00 0303510557 OBSERVATION DIRECT ADM CVCU 130.00 0303520275 CENTRAL LINE CATH INSERT BUCKT 318.00 0303520287 SUPPLIES CHEST TUBE 228.00 0303521666 SAFEGUARD PRESSURE BANDAGE 119.00 0303521958 SAFEGUARD PRESSURE BANDAGE 122.00 0303550451 IV INF THERAPEUTIC EA ADD HR 170.00 0303550453 IV INF THERAPEUTIC UP TO 1HR 635.00 0303550480 INSERT VENOUS CENTRAL LINE 2,690.00 0303550490 IV PUSH INITIAL DRUG 380.00 0303550603 IV PUSH EA SEQUENTIAL DRUG 153.00 0303550648 HEMODIALYSIS SERVICE IP 1,455.00 0303550777 CARDIOVERSION ELECTIVE 1,590.00 0303550885 ADMININSTRATION IMMUNIZATION 145.00 0303550948 DIALYSIS INTRAPERITONEAL SERVI 655.00 0303560002 INJECTION SUB-Q/IM 155.00 0303560057 CRRT-HEMO SERVICE 1,555.00 0303560101 HEMODIALYSIS SERVICE OBS/OP 1,455.00 0303560229 ECMO/RVAD PER 24HR SERVICE 2,010.00 0303560269 US PV RESIDUAL URINE 240.00 0303560274 IV PUSH EA ADD DRUG 168.00 0303560275 IV INF CONCURRENT THERAPEUTIC 385.00 0303560276 IV INF SEQUENTIAL THER UP TO 1 191.00 0303560373 IV INF HYDRATION EA ADD HR 138.00 0303560374 IV INF HYDRATION UP TO 1HR 430.00 0303560696 BLOOD TRANSFUSION DAILY 1,250.00 0303560928 THORACENTESIS ASP W IMAGING 2,105.00 0303561072 PLASMAPHERESIS SERVICE 2,965.00 0303561208 PORT FLUSH 190.00 0303590136 ADMIN INFLUENZA VACCINE 94.00
Recommended publications
  • Personalized Medicine for Reconstruction of Critical-Size Bone

    Personalized Medicine for Reconstruction of Critical-Size Bone

    www.nature.com/npjregenmed ARTICLE OPEN Personalized medicine for reconstruction of critical-size bone defects – a translational approach with customizable vascularized bone tissue ✉ Annika Kengelbach-Weigand 1 , Carolina Thielen 1, Tobias Bäuerle2, Rebekka Götzl 1,5, Thomas Gerber3, Carolin Körner4, Justus P. Beier1,5, Raymund E. Horch 1 and Anja M. Boos1,5 Tissue engineering principles allow the generation of functional tissues for biomedical applications. Reconstruction of large-scale bone defects with tissue-engineered bone has still not entered the clinical routine. In the present study, a bone substitute in combination with mesenchymal stem cells (MSC) and endothelial progenitor cells (EPC) with or without growth factors BMP-2 and VEGF-A was prevascularized by an arteriovenous (AV) loop and transplanted into a critical-size tibia defect in the sheep model. With 3D imaging and immunohistochemistry, we could show that this approach is a feasible and simple alternative to the current clinical therapeutic option. This study serves as proof of concept for using large-scale transplantable, vascularized, and customizable bone, generated in a living organism for the reconstruction of load-bearing bone defects, individually tailored to the patient’s needs. With this approach in personalized medicine for the reconstruction of critical-size bone defects, regeneration of parts of the human body will become possible in the near future. npj Regenerative Medicine (2021) 6:49 ; https://doi.org/10.1038/s41536-021-00158-8 1234567890():,; INTRODUCTION vascular networks consisting of endothelial cells can be created Therapeutic options for bone defects that cannot heal sponta- directly within tissue replacement materials7. Vascularization may neously, the so-called critical-size bone defects, are still limited be further supported by the addition of endothelial cells and and often associated with a great social burden.
  • Properties and Units in Clinical Pharmacology and Toxicology

    Properties and Units in Clinical Pharmacology and Toxicology

    Pure Appl. Chem., Vol. 72, No. 3, pp. 479–552, 2000. © 2000 IUPAC INTERNATIONAL FEDERATION OF CLINICAL CHEMISTRY AND LABORATORY MEDICINE SCIENTIFIC DIVISION COMMITTEE ON NOMENCLATURE, PROPERTIES, AND UNITS (C-NPU)# and INTERNATIONAL UNION OF PURE AND APPLIED CHEMISTRY CHEMISTRY AND HUMAN HEALTH DIVISION CLINICAL CHEMISTRY SECTION COMMISSION ON NOMENCLATURE, PROPERTIES, AND UNITS (C-NPU)§ PROPERTIES AND UNITS IN THE CLINICAL LABORATORY SCIENCES PART XII. PROPERTIES AND UNITS IN CLINICAL PHARMACOLOGY AND TOXICOLOGY (Technical Report) (IFCC–IUPAC 1999) Prepared for publication by HENRIK OLESEN1, DAVID COWAN2, RAFAEL DE LA TORRE3 , IVAN BRUUNSHUUS1, MORTEN ROHDE1, and DESMOND KENNY4 1Office of Laboratory Informatics, Copenhagen University Hospital (Rigshospitalet), Copenhagen, Denmark; 2Drug Control Centre, London University, King’s College, London, UK; 3IMIM, Dr. Aiguader 80, Barcelona, Spain; 4Dept. of Clinical Biochemistry, Our Lady’s Hospital for Sick Children, Crumlin, Dublin 12, Ireland #§The combined Memberships of the Committee and the Commission (C-NPU) during the preparation of this report (1994–1996) were as follows: Chairman: H. Olesen (Denmark, 1989–1995); D. Kenny (Ireland, 1996); Members: X. Fuentes-Arderiu (Spain, 1991–1997); J. G. Hill (Canada, 1987–1997); D. Kenny (Ireland, 1994–1997); H. Olesen (Denmark, 1985–1995); P. L. Storring (UK, 1989–1995); P. Soares de Araujo (Brazil, 1994–1997); R. Dybkær (Denmark, 1996–1997); C. McDonald (USA, 1996–1997). Please forward comments to: H. Olesen, Office of Laboratory Informatics 76-6-1, Copenhagen University Hospital (Rigshospitalet), 9 Blegdamsvej, DK-2100 Copenhagen, Denmark. E-mail: [email protected] Republication or reproduction of this report or its storage and/or dissemination by electronic means is permitted without the need for formal IUPAC permission on condition that an acknowledgment, with full reference to the source, along with use of the copyright symbol ©, the name IUPAC, and the year of publication, are prominently visible.
  • No. 33981 2 No

    No. 33981 2 No

    Pretoria, 4 February 2011 Februarle No. 33981 2 No. 33981 GOVERNMENT GAZETTE, 4 FEBRUARY 2011 IMPORTANT NOTICE The Government Printing Works will not be held responsible for faxed documents not received due to errors on the fax machine or faxes received which are unclear or incomplete. Please be advised that an "OK" slip, received from a fax machine, will not be accepted as proof that documents were received by the GPW for printing. If documents are faxed to the GPW it will be the sender's respon­ sibility to phone and confirm that the documents were received in good order. Furthermore the Government Printing Works will also not be held responsible for cancellations and amendments which have not been done on original documents received from clients. CONTENTS INHOUD Bladsy Koerant Page Gazette No. No. No. No. No. No. GENERAL NOTICE ALGEMENEKENNISGEWING Health, Department of Gesondheld, Departement van General Notice A/gemene Kennisgewing 58 Medicines and Related Substances Act 58 Wet op Beheer van Medisyne en (101/1965): Medicines Control Council: Verwante Stowwe (101/1965): Conditions of registration of a medicine Medisynebeheerraad: Voorwaardes vir in terms of the provisions of section die registrasie van 'n medisyne in terme 15 (7) ..................................................... .. 3 33981 van die bepalings van artikel 15 (7) ........ 4 33981 STAATSKOERANT, 4 FEBRUARIE 2011 No. 33981 3 GENERAL NOTICE ALGEMENE KENNISGEWING NOTICE 58 OF 2011 MEDICINES CONTROL COUNCIL CONDITIONS OF REGISTRATION OF A MEDICINE IN TERMS OF THE PROVISIONS OF SECTION 15(7) OF THE MEDICINES AND RELATED SUBSTANCES ACT, 1965 (ACT 101 OF 1965) 1. The applicant shall ensure that the medicine is manufactured and controlled in terms of the current Good Manufacturing Practices as determined by Council 2.
  • Mcneil Consumer : Mdl No

    Mcneil Consumer : Mdl No

    IN THE UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF PENNSYLVANIA IN RE: MCNEIL CONSUMER : MDL NO. 2190 HEALTHCARE, ET AL., MARKETING : AND SALES PRACTICES LITIGATION : : Applies to: : ALL ACTIONS : MEMORANDUM McLaughlin, J. July 13, 2012 This multidistrict litigation arises out of quality control problems at the defendants’ facility manufacturing over- the-counter healthcare products in Fort Washington, Pennsylvania, which led to a series of recalls of those products. The named plaintiffs assert claims for economic loss on behalf of a putative nationwide class against Johnson & Johnson (“J&J”), McNeil Consumer Healthcare (“McNeil”), and four of their executives. The plaintiffs allege that they overpaid for the defendants’ products as a result of the recalls and the defendants’ scheme to conceal or downplay the scope of the quality control problems. The defendants, who have offered a coupon or cash refund to consumers who purchased recalled drugs, have moved to dismiss the operative complaint, and assert that the named plaintiffs lack constitutional standing and have not met the applicable pleading standard. The Court will grant the defendants’ motion because the plaintiffs have not pled facts that show a cognizable injury in fact, which is required to confer Article III standing. I. Procedural Background This litigation resulted from the consolidation of ten individual actions filed around the country. Haviland v. McNeil Consumer Healthcare, No. 10-2195, was filed in this Court on May 12, 2010, asserting economic injuries arising out of the April 30, 2010 recall of over-the-counter children’s drugs by McNeil, a part of the J&J “Family of Companies.” Eight additional cases, also arising out of the April 2010 recall, were filed in district courts around the country.1 All cases asserted claims for economic injury only, with the exception of Rivera v.
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1

    Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1

    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
  • Notice Under S66 of the Commerce Act 1986 Application by Johnson & Johnson to Acquire the Stock, Assets and Business Of

    Notice Under S66 of the Commerce Act 1986 Application by Johnson & Johnson to Acquire the Stock, Assets and Business Of

    PUBLIC COPY Notice under s66 of the Commerce Act 1986 Application by Johnson & Johnson to acquire the stock, assets and business of the Consumer Healthcare division of Pfizer Inc. COMMERCE ACT 1986: BUSINESS ACQUISITION SECTION 66: NOTICE SEEKING CLEARANCE 28 September 2006 The Registrar Business Acquisitions and Authorisations Commerce Commission PO Box 2351 Wellington Pursuant to s66(1) of the Commerce Act 1986 notice is hereby given seeking clearance of a proposed business acquisition. 518689_1.DOC 2 CONTENTS EXECUTIVE SUMMARY PART 1: TRANSACTION DETAILS 1 The business acquisition for which clearance is sought 2 The person giving this notice 3 Confidentiality 4 Participants 5 Interconnected and associated persons 6 Beneficial interests 7 Links between participants 8 Common directorships 9 Business activities of the participants 10 Reasons for the proposed acquisition PART II: IDENTIFICATION OF MARKETS AFFECTED 11 Horizontal aggregation 12 Differentiated product markets 13 Differentiated product markets 14 Vertical integration 15 Other business acquisitions PARTS III, IV AND V: CONSTRAINTS ON MARKET POWERS BY EXISTING AND POTENTIAL COMPETITION AND OTHER POTENTIAL CONSTRAINTS 16 Allergy medication 17 Products for the treatment of worms 18 Thrush treatment CERTIFICATE APPENDICES 1. Heartburn and indigestion remedies (MYLANTA and MOTILIUM) 2. Worm treatments (COMBANTRIN, VERMOX) 3. Cold, flu, nasal decongestant, cough relief and sort throat medications (CODRAL, SINUTAB, SUDAFED, BENADRYL, BRONDECON) 4. Allergy relief products (ACTIFED, SINUTAB, SUDAFED, VISINE, LIVOSTIN) 518689_1.DOC 3 5. Thrush treatments (DIFLUCAN ONE, DAKTARIN, DAKTAGOLD, NIZORAL, SPORANOX) 6. Shampoo (PREGAINE, ROGAINE, NEUTROGENA, JOHNSON’S BABY SHAMPOO) 7. Hand hygiene (PURELL and MICRO SHIELD) 8. Competitor worm treatment products 9. Multinational pharmaceutical businesses: GlaxoSmithKline, Douglas Pharmaceuticals, Alphapharm, Bayer Group 10.
  • Medication Code Key: PMCODE and Drug Name in 2007 NHHCS Cdc-Pdf

    Medication Code Key: PMCODE and Drug Name in 2007 NHHCS Cdc-Pdf

    Medication Code Key: PMCODE and Drug Name in 2007 NHHCS PMCODE Drug Name 00002 TAMIFLU 00003 DITROPAN XL II 00004 LIDODERM PATCH 00008 VIACTIV 00010 A AND D II 00013 MYCOPHENOLATE MOFETIL 00017 SIROLIMUS 00019 HAWTHORN 00027 SYNAGIS 00032 EXCEDRIN MIGRAINE 00036 MAALOX PLUS 00037 ACEON 00038 GLYSET 00039 SONATA 00042 PROTONIX 00044 PANLOR DC 00048 MOBIC 00052 SILDENAFIL CITRATE 00053 TAMSULOSIN HYDROCHLORIDE 00054 COMTAN 00058 MINERAL SUPPLEMENT 00061 BISMUTH 00071 CERTAVITE 00073 LUXIQ 00075 SAL-TROPINE 00076 TRILEPTAL 00078 AGGRENOX 00080 CARBIDOPA-LEVODOPA 00081 EXELON 00084 PREGABALIN 00085 ORAMORPH 00096 OSTEO-BIFLEX 00099 ALOCRIL 00100 A.S.A. 00101 ISOSORBIDE DINITRATE 00102 ISOSORBIDE MONONITRATE 00107 ROSIGLITAZONE MALEATE 00109 URSODIOL 00112 MEDERMA 00113 ANDROGEL 00114 DILTIA XT 00117 CRANBERRY 00123 NICOTINE 00125 AVELOX 00132 CAL-MAG 00133 CANDESARTAN Page 1 Medication Code Key: PMCODE and Drug Name in 2007 NHHCS PMCODE Drug Name 00148 PROLIXIN D 00149 D51/2 NS 00150 NICODERM CQ PATCH 00151 TUSSIN 00152 CEREZYME 00154 CHILDREN'S IBUPROFEN 00156 PROPOXACET-N 00159 KALETRA 00161 BISOPROLOL 00167 NOVOLIN N 00169 KETOROLAC TROMETHAMINE 00172 OPHTHALMIC OINTMENT 00173 ELA-MAX 00176 PREDNISOLONE ACETATE 00179 COLLOID SILVER 00184 KEPPRA 00187 OPHTHALMIC DROPS 00190 ABDEC 00191 HAPONAL 00192 SPECTRAVITE 00198 ENOXAPARIN SODIUM 00206 ACTONEL 00208 CELECOXIB 00209 GLUCOVANCE 00211 LEVALL 5.0 00213 PANTOPRAZOLE SODIUM 00217 TEMODAR 00218 CARBAMIDE PEROXIDE 00221 CHINESE HERBAL MEDS 00224 MILK AND MOLASSES ENEMA 00238 ZOLMITRIPTAN 00239
  • Partial Agreement in the Social and Public Health Field

    Partial Agreement in the Social and Public Health Field

    COUNCIL OF EUROPE COMMITTEE OF MINISTERS (PARTIAL AGREEMENT IN THE SOCIAL AND PUBLIC HEALTH FIELD) RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies, and superseding Resolution AP (82) 2) AND APPENDIX I Alphabetical list of medicines adopted by the Public Health Committee (Partial Agreement) updated to 1 July 1988 APPENDIX II Pharmaco-therapeutic classification of medicines appearing in the alphabetical list in Appendix I updated to 1 July 1988 RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (superseding Resolution AP (82) 2) (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies) The Representatives on the Committee of Ministers of Belgium, France, the Federal Republic of Germany, Italy, Luxembourg, the Netherlands and the United Kingdom of Great Britain and Northern Ireland, these states being parties to the Partial Agreement in the social and public health field, and the Representatives of Austria, Denmark, Ireland, Spain and Switzerland, states which have participated in the public health activities carried out within the above-mentioned Partial Agreement since 1 October 1974, 2 April 1968, 23 September 1969, 21 April 1988 and 5 May 1964, respectively, Considering that the aim of the Council of Europe is to achieve greater unity between its members and that this
  • TITLE Safety and Efficacy of Over-The-Counter Drug Use by the Elderly

    TITLE Safety and Efficacy of Over-The-Counter Drug Use by the Elderly

    " DOCUMENT RESUME ED 245 148 CG 017 518 TITLE Safety and Efficacy of Over-the-Counter Drug Use by the Elderly. Hearing before the Subcommittee on Health and Long-Term Care of the Select Committee on Aging. House of Representatives, Ninety-Eighth Congress, First Session. INSTITUTION Congress of the U.S., Washington, D.C. House Select Committee on Aging. REPORT NO House-Comm-Pub-98-409 PUB DATE 21 Jul 83 NOTE 507p.; Some pages are marginally legible due to small print. PUB TYPE Legal/Legislative/Regulatory Materials (090) EDRS PRICE MF02 Plus Postage. PC Not Available from EDRS. DESCRIPTORS *Consumer Protection; Dietetics; Drug Legislation; *Drug Use; Gerontology; Hearings; *Older Adults; Physical Health; *Safety IDENTIFIERS Congress 98th; Long Term Care; *Nonprescription Drugs; *PPA ABSTRACT This document contains the prepared statements and panel testimony from the Congressional hearing on over-the-counter (OTC) drug use by the elderly. Opening statements are given by Representatives Claude Pepper (chairman), Ralph Regula, Mary Rose Oakar, Michael Bilirakis, Tom Lantos, and Hal Daub. Topics which are covered include the incidence and quantity of drug use by the elderly, health risks, adverse reactions, phenylpropanolamine (PPA), consumer protection, and the Federal Drug Administration's (FDA) role in the OTC drug safety and reguIatiem. Testimony of the first panel on OTC drugs, particularly weight reduction medications containing PPA, is given by representatives of the Health Research Group, the National Broadcasting Company, and consumers. Testimony of the second panel on mail fraud schemes perpetrated against senior citizens is given by consumer advocates representing the United States Postal Service, Criminal Investigations and Consumer Protection Divisions, and the Center for Science in the Public Interest.
  • 116561 18 G IV Cath Needle, Sterile $5.00 116577 20 G IV Cath Needle

    116561 18 G IV Cath Needle, Sterile $5.00 116577 20 G IV Cath Needle

    Charge Code Description Fee 116561 18 G IV Cath needle, sterile $5.00 116577 20 G IV Cath needle, sterile $5.00 116588 22 G IV Cath needle, sterile $5.00 118216 5% dextrose/NS (500 ml = 1 unit) $75.00 118237 5% Dextrose/Water, 250 ml $10.00 118229 5% Dextrose/Water, 500 ml $10.00 117453 Acet/Tylenol #3 with Codeine, 300mg, Oral $7.88 117515 Acet/Tylenol drops, 80mg $7.88 117525 Acet/Tylenol w/ Codeine, 12.5mg, Elixer $7.88 117467 Acet/Tylenol, 120mg, Suppository $7.88 117493 Acet/Tylenol, 325 mg, PO $7.88 117523 Acetaminophen/Tylenol Elixir, 160mg $7.88 117483 Acetaminophen/Tylenol, 160 mg, chewable tablet $7.88 117498 Acetaminophen/Tylenol, 500 mg tablet $7.88 117514 Acetaminophen/Tylenol, 60mg suppository $7.88 117528 Activated Charcoal, 25mg with Sorbital, Suspension $25.00 116826 Adaptic / Gel sheet / Kling for dermal or epidermal application, each $23.63 117046 Adenosine for therapeutic use, 6 mg (vial), IV $490.35 116958 Administration set, with small volume nonfiltered pneumatic nebulizer, disposable $35.00 117061 Adrenalin, Epinephrine, 0.1 mg, IV/IM/SC $42.00 117715 Adult-Fleet Enema $10.00 116967 Aerosol mask, used with DME nebulizer $15.00 117535 Afrin Nasal Spray (Oxymetazoline) $7.88 115336 Albumin; serum, plasma or whole blood $71.00 118279 Albuterol, inhalation solution, unit dose (per vial) $20.00 118293 Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, $40.00 115301 Alcohol Level, Blood (ETOH) $36.00 116615 Alcohol or peroxide, per pint $2.00 116076 Alligator Forceps $137.81 117538 Amidate / Etomidate 2mg,
  • Annual Report

    Annual Report

    ANNUAL REPORT 2019 MARCH 2020 To Our Shareholders Alex Gorsky Chairman and Chief Executive Officer By just about every measure, Johnson & These are some of the many financial and Johnson’s 133rd year was extraordinary. strategic achievements that were made possible by the commitment of our more than • We delivered strong operational revenue and 132,000 Johnson & Johnson colleagues, who adjusted operational earnings growth* that passionately lead the way in improving the health exceeded the financial performance goals we and well-being of people around the world. set for the Company at the start of 2019. • We again made record investments in research and development (R&D)—more than $11 billion across our Pharmaceutical, Medical Devices Propelled by our people, products, and and Consumer businesses—as we maintained a purpose, we look forward to the future relentless pursuit of innovation to develop vital with great confidence and optimism scientific breakthroughs. as we remain committed to leading • We proudly launched new transformational across the spectrum of healthcare. medicines for untreated and treatment-resistant diseases, while gaining approvals for new uses of many of our medicines already in the market. Through proactive leadership across our enterprise, we navigated a constant surge • We deployed approximately $7 billion, of unique and complex challenges, spanning primarily in transactions that fortify our dynamic global issues, shifting political commitment to digital surgery for a more climates, industry and competitive headwinds, personalized and elevated standard of and an ongoing litigious environment. healthcare, and that enhance our position in consumer skin health. As we have experienced for 133 years, we • And our teams around the world continued can be sure that 2020 will present a new set of working to address pressing public health opportunities and challenges.
  • Otc) Benefit Medication Formulary

    Otc) Benefit Medication Formulary

    OVER-THE-COUNTER (OTC) BENEFIT MEDICATION FORMULARY The OTC formulary is a list of medicines (Schedule 0-3) that will be paid from the OTC benefit, subject to the limit specified by the scheme. Metropolitan Generic Reference Price (METREF) will apply. Co-payments will apply for items amounting to more than the reference price. The formulary is subject to regular review. Metropolitan Health reserves the right to update and change the formulary when new information becomes available. IMPORTANT: Please note that the medication on this list is published on an annual basis. Medication and prices are subject to change based on new clinical information and/or pricing updates which may not be reflected on the list below. Product name Active Ingredient Strength Dosage form Schedule Nappi code Oral antiseptics and sore throat Andolex C Benzydamide SPR 1 710149 Andolex Oral Rinse Benzydamide . MOW 1 810576 Andolex Spray Benzydamide . SPR 1 816167 Betadine oral Povidone-iodine MOW 0 707937 Dermadine oral garg Povidone-iodine 1g/100ml MOW 0 799688 Iodised throat Antiseptics LOZ 1 892670 Iodised throat Antiseptics LOZ 1 810010 Medi-keel A Cetylpyridinium LOZ 1 741035 Medi-Keel A black currant Cetylpyridinium LOZ 1 884233 Medi-Keel A honey & lemon Cetylpyridinium LOZ 1 884225 Podine mouth wash Povidone-iodine MOW 0 785210 Septadine oral antiseptic Povidone-iodine MOW 0 819859 Steridine mouthwash and gargle liquid Povidone-iodine MOW 0 890365 Tcp antiseptic Antiseptics SLN 1 815950 Throflam Benzydamide MOW 1 712171 Throflam Benzydamine 22.5mg/15ml